PEPTIDE

Tesamorelin

Tesamorelin is a stabilized 44-amino acid synthetic analog of human growth hormone-releasing hormone (GHRH). It is the only FDA-approved GHRH analog (marketed as Egrifta) for reducing visceral adipose tissue in HIV-associated lipodystrophy, and stimulates physiological pulsatile endogenous growth hormone (GH) and IGF-1 secretion to support selective visceral fat loss and metabolic regulation in research.

Tesamorelin is a metabolically stabilized 44-amino acid synthetic analog of human GHRH, modified with a trans-3-hexenoic acid moiety to enhance bioavailability and resistance to enzymatic degradation. It is the only GHRH analog with full FDA clinical approval, and a gold-standard research tool for growth hormone and metabolic regulation studies:

Core Mechanism & Key Properties

Selectively binds to GHRH receptors on pituitary somatotroph cells, stimulating physiological pulsatile endogenous GH secretion that replicates natural hypothalamic regulation (unlike the continuous supraphysiological GH levels caused by exogenous GH administration)
Elevates circulating IGF-1 levels via GH-mediated hepatic signaling, mediating selective lipolytic, anabolic, and metabolic effects
Preferentially mobilizes visceral adipose tissue (VAT, internal organ fat) with minimal impact on subcutaneous fat: Phase 3 clinical trials demonstrated 15–18% VAT reduction over 26 weeks at standard dosing

Primary Research Applications

Preclinical and clinical studies of HIV-associated lipodystrophy and pathological visceral adiposity
Metabolic research into GH-mediated lipid regulation, body composition modulation, and insulin sensitivity
Investigations of physiological GH secretion patterns and anabolic effects without the receptor suppression risks of exogenous GH

Manufactured to ≥98% purity, sterile-filtered, and lyophilized for long-term storage stability.

For laboratory research use only; not intended for human or veterinary administration outside of approved clinical protocols.

Request Quote / COA